EP303: The Conflict Between QALYs for Drug Value and Specific Well-Funded Patient Advocacy Groups, With Anna Kaltenboeck From the Drug Pricing Lab at Memorial Sloan Kettering

In Episode 303, Stacey Richter talks with Anna Kaltenboeck, senior health economist and program director for the Drug Pricing Lab at Memorial Sloan Kettering, about QALYs — the "ruler" used to measure the value of a drug so society has a consistent benchmark for what to pay.

WHAT YOU'LL LEARN

✅ What a QALY (quality-adjusted life year) actually measures and why it exists

✅ The three components that go into a QALY calculation: added survival, quality of life, and societal willingness to pay

✅ Why willingness to pay varies by both country and condition

✅ What role ICER plays in producing independent QALY-based drug assessments

✅ Where value-based pricing fits into the broader QALY framework

WHY THIS MATTERS

Anna Kaltenboeck breaks down QALYs as a kind of universal ruler for drug value — a way to make an apples-to-apples comparison so that a dollar of value means the same thing across different drugs and different patients. The calculation combines how much a drug extends survival, how it affects quality of life, and how much society is willing to pay for that improvement. It's an imperfect tool, and not everyone agrees on how well it works, but it gives patients, payers, and pharma a shared framework for asking whether a drug's price actually matches the benefit it delivers.

=== LINKS ===

🔗 Show Notes with all mentioned links: Episode Page

🔗 Healthcare Industry Acronyms and Terms

✉️ Enjoy this podcast? Subscribe to the free weekly newsletter

🫙 Support the podcast with a small donation to the Tip Jar

📺 Subscribe to our YouTube channel

🎤 Listen on Apple Podcasts

🎤 Listen on Spotify

=== CONNECT WITH THE RHV TEAM ===

✭ LinkedIn ✭ Threads ✭ Bluesky ✭ X

00:00 Introduction.

03:56 What is a QALY?

05:28 "You don't get marks; it's the treatment that gets the marks."

09:13 What is willingness to pay?

10:52 "What we pay for drugs should be reflected in societal preference."

12:29 Does Pharma fear the QALY?

15:38 "At the end of the day, the ideal here is simply to be able to quantify 'This is what we're going to pay for this additional benefit that we're going to provide for patients.'"

17:09 "When you meet that price, patients should be getting access to that product."

19:27 What are the significant advances being seen with QALYs and drug development?

21:23 "The challenge is when the price is so much higher than those benchmarks."

22:27 How do we use the QALY as a tool?

25:56 Where does value-based pricing fall in the world of QALYs?